The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Refractory acute lymphocytic leukemia (ALL) presents a significant treatment challenge.
• Salvage chemotherapy options for relapsed ALL are critical for improving patient outcomes.

Purpose of the Study:

• To compare the efficacy and toxicity of the hyper-CVAD regimen versus high-dose Ara-C-based regimens in adults with refractory ALL.
• To evaluate survival and disease-free survival rates between the two treatment groups.

Main Methods:

• A cohort of 66 adults with refractory ALL received salvage therapy with the hyper-CVAD regimen.
• Outcomes were compared to 63 historical control patients treated with high-dose Ara-C plus mitoxantrone, with or without GM-CSF.
• Complete response rates, resistance patterns, granulocyte recovery time, and survival were analyzed.

Main Results:

• Complete response rates were similar (44% vs 38%).
• Hyper-CVAD showed a trend towards less secondary resistance (29% vs 44%) and significantly more primary resistance (15% vs 2%).
• Granulocyte recovery was faster with hyper-CVAD (20 vs 25 days).
• Survival was prolonged with hyper-CVAD (42 vs 20 weeks), particularly in first salvage patients (P=0.016).
• Disease-free survival was significantly better for first salvage patients on hyper-CVAD (52 vs 20 weeks, P=0.008).

Conclusions:

• The hyper-CVAD regimen is a more effective salvage therapy for relapsed acute lymphocytic leukemia.
• Hyper-CVAD demonstrates improved survival and faster hematologic recovery compared to high-dose Ara-C-based regimens.
• This regimen offers a less toxic alternative for patients with refractory ALL.